← Leaderboards
Jason W. Rosch
St. Jude Children'S Research Hospital
$10,977,689
Attributed
$22,817,907
Total exposure
13
Grants
11
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $6M · FY2008–25$10M$7.5M$5M$2.5M$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$32,811,608 · 14
By mechanism
U19$13,402,789 · 3
U01$10,213,678 · 1
R01$7,569,057 · 4
R21$987,350 · 2
R56$531,058 · 1
F32$102,208 · 1
Top collaborators
- Tim Van Opijnen13 shared
- Vaughn Cooper9 shared
- Ralph R Isberg9 shared
- Jose Bento5 shared
- Federico Antonio Rosconi4 shared
- Stacey L Schultz-Cherry4 shared
- Elisa B H Margolis2 shared
- Amanda Marie Green1 shared
Most similar at St. Jude Children'S Research Hospital
Same institution · by research overlap
- Stacey L Schultz-Cherry$5,391,169
- Tim Van Opijnen$11,046,881
- Elisa B H Margolis$755,213
- Juan Cesar Federico Ortiz-Marquez$1,074,904
- Shyra Wilde$75,520
Others in their field
Top investigators on “Streptococcus Pneumoniae”
- Jeffrey N. Weiser · New York University School Of Medicine$20,590,649
- Dallas Hughes · Novobiotic Pharmaceuticals, Llc$15,114,161
- Elaine Tuomanen · University Of Alabama At Birmingham$13,568,473
- Liise-Anne Pirofski · Yeshiva University$13,441,639
- Joseph P Mizgerd · Boston University Medical Campus$12,549,527
- Myron Max Levine · University Of Maryland Baltimore$12,500,000
Research focus
Streptococcus PneumoniaeInfectionMutantPathway InteractionsGenesPathogenIn VivoPreventGeneticFitnessSynergismStressAntibiotic ResistanceEvolutionIn VitroMutationEnvironmentComplexAntibioticsResponsePhenotypeTranscriptome SequencingVirulenceGenomics
Grant awards (36)
Attacking failure of antibiotic treatment by targeting antimicrobial resistance enabler cell-states$2,470,464
U19 · FY2025 · AI
[18F]fluoromannitol: A novel imaging agent to delineate osteomyelitis in sickle cell disease$894,735
R01 · FY2025 · AI
Collateral Consequences of Enabler Genotypes in Antibiotic Treatment Failure.$770,793
U19 · FY2025 · AI · contact PI
Evolvable essentiality in the pan-genome of Streptococcus pneumoniae and its mechanistic and evolutionary consequences$607,872
R01 · FY2025 · AI · contact PI
Consequences of Direct Viral-Bacterial Interactions$487,212
R01 · FY2025 · AI · contact PI
Characterization of TCS11 in Streptococcus pneumoniae$220,675
R21 · FY2025 · AI · contact PI
Trivalent Live Attenuated Vaccines for Bacterial Acute Otitis Media$220,675
R21 · FY2025 · AI · contact PI
Attacking failure of antibiotic treatment by targeting antimicrobial resistance enabler cell-states$2,588,682
U19 · FY2024 · AI
Collateral Consequences of Enabler Genotypes in Antibiotic Treatment Failure.$1,774,417
U19 · FY2024 · AI · contact PI
Evolvable essentiality in the pan-genome of Streptococcus pneumoniae and its mechanistic and evolutionary consequences$607,872
R01 · FY2024 · AI · contact PI
Consequences of Direct Viral-Bacterial Interactions$502,279
R01 · FY2024 · AI · contact PI
Characterization of TCS11 in Streptococcus pneumoniae$273,000
R21 · FY2024 · AI · contact PI
Trivalent Live Attenuated Vaccines for Bacterial Acute Otitis Media$273,000
R21 · FY2024 · AI · contact PI
Attacking failure of antibiotic treatment by targeting antimicrobial resistance enabler cell-states$2,571,561
U19 · FY2023 · AI
Evolvable essentiality in the pan-genome of Streptococcus pneumoniae and its mechanistic and evolutionary consequences$601,612
R01 · FY2023 · AI · contact PI
Consequences of Direct Viral-Bacterial Interactions$502,279
R01 · FY2023 · AI · contact PI
Collateral Consequences of Enabler Genotypes in Antibiotic Treatment Failure.$425,112
U19 · FY2023 · AI · contact PI
Attacking failure of antibiotic treatment by targeting antimicrobial resistance enabler cell-states$2,362,994
U19 · FY2022 · AI
Evolvable essentiality in the pan-genome of Streptococcus pneumoniae and its mechanistic and evolutionary consequences$617,417
R01 · FY2022 · AI · contact PI
Consequences of Direct Viral-Bacterial Interactions$522,779
R01 · FY2022 · AI · contact PI
Collateral Consequences of Enabler Genotypes in Antibiotic Treatment Failure.$438,766
U19 · FY2022 · AI · contact PI
Consequences of Direct Viral-Bacterial Interactions$531,058
R56 · FY2021 · AI · contact PI
Predicting the emergence of antibiotic resistance through multi-omics approaches and Immune System-surveillan$1,876,314
U01 · FY2020 · AI
Predicting the emergence of antibiotic resistance through multi-omics approaches and Immune System-surveillan$1,895,142
U01 · FY2019 · AI
Pneumococcal pathogenesis in sickle cell disease$445,000
R01 · FY2019 · AI · contact PI
Predicting the emergence of antibiotic resistance through multi-omics approaches and Immune System-surveillan$2,262,413
U01 · FY2018 · AI
Pneumococcal pathogenesis in sickle cell disease$445,000
R01 · FY2018 · AI · contact PI
Predicting the emergence of antibiotic resistance through multi-omics approaches and Immune System-surveillan$2,209,004
U01 · FY2017 · AI
Pneumococcal pathogenesis in sickle cell disease$445,000
R01 · FY2017 · AI · contact PI
Predicting the emergence of antibiotic resistance through multi-omics approaches and Immune System-surveillan$1,970,805
U01 · FY2016 · AI
Pneumococcal pathogenesis in sickle cell disease$445,000
R01 · FY2016 · AI · contact PI
Pneumococcal pathogenesis in sickle cell disease$445,000
R01 · FY2015 · AI · contact PI
Bacterial cation exporters: a new signaling paradigm for bacterial virulence$52,154
F32 · FY2010 · AI · contact PI
Bacterial cation exporters: a new signaling paradigm for bacterial virulence$50,054
F32 · FY2009 · AI · contact PI
ANIONIC LIPIDS ENRICHED AT THE EXPORTAL OF STREPTOCOCCUS PYOGENES$2,791
P41 · FY2009 · RR · contact PI
ANIONIC LIPIDS ENRICHED AT THE EXPORTAL OF STREPTOCOCCUS PYOGENES$2,677
P41 · FY2008 · RR · contact PI